Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. - Wikidata - wikimedia - TriplyDB

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

http://www.wikidata.org/entity/Q36107130

about

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells PharmGKB summary: tamoxifen pathway, pharmacokinetics Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells.Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

P2860

Q28546094-86D0E351-DC36-4720-A30F-EDD4FFED2CF7 Q33855494-B00A2048-A968-434A-9178-1AFA947B636B Q34360041-A7303B50-A8F6-40FE-8326-7607EE33AEBB Q34736075-B5736E7F-9ED7-4463-BF1C-753B8CC8D670 Q35732619-DCEA9CB0-7777-44CB-A6D1-0A5975B6B4E4 Q37179748-80D0BD09-2D57-42A9-9407-42BF4E0B7460 Q37202495-10C60FCA-A5AA-4C97-B944-8734B9627ACE Q37604428-12ED7262-B99B-4795-903A-8F12FE3CBAF1 Q38171391-4C8C2B9D-DE5B-415C-A7AE-B6D0FEE10DC2 Q38968554-2128554A-C435-4D41-969B-CEE3F353FE23 Q45905355-C0D4EDAD-73DE-400F-B86E-82742117F052

P2860

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

http://www.wikidata.org/entity/Q36107130

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@ast

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@en

type

label

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@ast

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@en

prefLabel

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@ast

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@en

P1433

Q36107130-1A23C38C-02A5-4C8D-9D29-2AF6FC2DD7B1

P1476

Q36107130-F3270B72-6745-4B6F-9428-7F4D452EAF3A

P2093

Q36107130-1E5CF2EA-F081-45E4-86BF-DFD0C27DD20C

Q36107130-614C4C0D-03A0-4BFC-B512-0E22B1E7DF4A

Q36107130-9F7B2E49-08F8-494C-92F6-6BB68174F3D4

Q36107130-AD404116-4A75-4D25-BD0D-20B31C60CD55

Q36107130-DA5214BF-6885-4CDF-8383-7051C0FE7D54

Q36107130-EB372338-7996-4358-B042-4401995841E5

Q36107130-EF039E93-AFFC-4A2E-92F1-2D152BC671D2

Q36107130-FE02A63B-0290-45E6-AA28-70EC6EF8BF3E

P2860

Q36107130-0D70F152-CBCB-403C-B1E8-EF37AAE29701

Q36107130-0E10343D-B0AC-4193-A059-1BA115624BB3

Q36107130-0F6FA2E0-F61E-4B23-B7CF-284119A16C12

Q36107130-146E4C93-02A6-439F-8262-4578DED1C8D4

Q36107130-15EF3B89-E442-4681-953D-D9E16EC59FCC

Q36107130-18816136-BE6E-49D1-9BB6-D7D6136D230C

Q36107130-1A587558-60E1-4285-AA78-4248D6542724

Q36107130-23516FD6-B686-40CF-A331-EDAE20204617

Q36107130-2A5C1763-3C23-434F-BCA0-AB561D8E19CF

Q36107130-2CDDB630-37FC-4186-95A8-11B150D54D01

P2888

Q36107130-64934988-8EEE-44D5-B48F-56EBBE817521

P304

Q36107130-58E8EC93-6788-403B-8FE1-A7EAB70A11F1

P31

Q36107130-A611371B-604B-4323-B38D-9B9F548DCACB

P356

Q36107130-3C38D094-711F-43D3-B47B-2ED42184723F

P407

Q36107130-C94CE133-381B-4F3E-A05A-C787E4E210CF

P433

Q36107130-ED8C644C-C4B9-410B-9FC7-B65F282D10BE

P478

Q36107130-9C411142-6F20-4CF9-8DD5-2CE5AFFDAD39

P577

Q36107130-7A0E2CF8-EDFA-4BC7-B835-2144844B2148

P5875

Q36107130-F7768351-E5A9-403D-B8EE-A531D8DC289E

P698

Q36107130-B9D569EE-1360-4D7D-B90D-5B81EB20EAB4

P932

Q36107130-21635C8A-2353-49C7-9F1A-F527FC788D33

P356

S10549-012-2074-9

P1433

Breast Cancer Research and Treatment

P1476

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

@en

P2093

Aliana Guerrieri-Gonzaga

http://www.w3.org/2001/XMLSchema#string

Andrea Decensi

http://www.w3.org/2001/XMLSchema#string

Ernst A Lien

http://www.w3.org/2001/XMLSchema#string

Gunnar Mellgren

http://www.w3.org/2001/XMLSchema#string

Jennifer Gjerde

http://www.w3.org/2001/XMLSchema#string

Line L Haugan Moi

http://www.w3.org/2001/XMLSchema#string

Sara Gandini

http://www.w3.org/2001/XMLSchema#string

Valentina Aristarco

http://www.w3.org/2001/XMLSchema#string

P2860

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

Genotype-guided tamoxifen therapy: time to pause for reflection?

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Overview of the main outcomes in breast-cancer prevention trials.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

P2888

s10549-012-2074-9

P304

693-700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2074-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224914651

http://www.w3.org/2001/XMLSchema#string

P698

22562123

http://www.w3.org/2001/XMLSchema#string

P932

3401496

http://www.w3.org/2001/XMLSchema#string